12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $4M | -$50222 | 56.7% | -1260.8% | 0.2% | -0.2% | -$25M | — | $12M |
| 2024 | $2M | -$60663 | 39.3% | -3245.1% | 0.5% | -0.2% | -$21M | — | $9M |
| 2023 | $2M | -$27781 | 27.5% | -1672.4% | -0.1% | -0.0% | -$24M | — | $9M |
| 2022 | $958000 | -$73M | -1.9% | -1878.6% | -212.6% | -72.8% | -$50M | — | $20M |
| 2021 | $2M | -$64M | 64.6% | -2444.3% | -98.3% | -40.2% | -$38M | — | $33M |
| 2020 | $1M | -$30M | -52.5% | -2443.3% | -89.4% | -54.0% | -$27M | — | $7M |
| 2019 | — | -$22M | — | — | -72.7% | -56.3% | -$21M | — | $22M |
| 2018 | — | -$16M | — | — | -460.2% | -165.5% | -$12M | — | $8M |
| 2017 | — | -$19M | — | — | -440.0% | -189.7% | -$13M | $2M | $8M |
| 2016 | — | -$11M | — | — | -113.2% | -77.3% | -$8M | — | $10M |
| 2015 | — | -$9M | — | — | -83.9% | -68.6% | -$5M | — | $8M |
| 2014 | — | -$5M | — | — | 464.2% | — | — | — | $257000 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $239000 | -$11M | 65.7% | -4770.7% | 52.9% | -38.2% | -$10M | — | $18M |
| Mar '26 | $32000 | -$4M | 46.9% | -13790.6% | 40.1% | -10.6% | -$8M | — | $28M |
| Dec '25 | $1M | -$23M | 43.5% | -2057.5% | 73.0% | -89.1% | -$7M | — | $12M |
| Sep '25 | $260000 | -$11M | 53.5% | -4249.2% | 118.0% | -24.7% | -$6M | — | $19M |
| Jun '25 | $518000 | -$10M | 65.3% | -1900.0% | -887.2% | -19.3% | -$7M | — | $24M |
| Mar '25 | $2M | -$7M | 62.0% | -318.0% | -65.3% | -11.1% | -$6M | — | $31M |
| Dec '24 | $1M | -$34M | 40.0% | -2262.9% | 273.0% | -95.5% | -$6M | — | $9M |
| Sep '24 | $115000 | -$13M | 43.5% | -11752.2% | -138.9% | -19.2% | -$6M | — | $3M |
| Jun '24 | $104000 | -$5M | 48.1% | -4453.8% | -20.0% | -6.1% | -$6M | — | $9M |
| Mar '24 | $176000 | -$9M | 25.6% | -5265.3% | -78.8% | -12.9% | -$4M | — | $6M |
| Dec '23 | $314000 | -$16M | -37.3% | -5152.5% | -78.1% | -21.4% | -$5M | — | $9M |
| Sep '23 | $429000 | -$6M | 57.8% | -1518.2% | -18.0% | -8.0% | — | — | $14M |
| Jun '23 | $463000 | -$8M | 58.7% | -1791.4% | -19.1% | -9.5% | — | — | $17M |
| Mar '23 | $297000 | $3M | 3.4% | 1969.7% | 8.0% | 3.7% | — | — | $12M |
| Dec '22 | $274000 | -$45M | -9.9% | -4251.1% | -131.2% | -44.9% | -$10M | — | $20M |
| Sep '22 | $67000 | -$9M | -401.5% | -2546.3% | -12.1% | -5.9% | -$12M | — | $32M |
| Jun '22 | $237000 | -$8M | 13.1% | -686.1% | -10.0% | -4.9% | -$12M | — | $45M |
| Mar '22 | $380000 | -$10M | 65.0% | -793.9% | -18.1% | -7.0% | -$15M | — | $20M |
| Dec '21 | -$2M | -$36M | -134.1% | 783.1% | -55.0% | -22.5% | -$7M | — | $33M |
| Sep '21 | $984000 | -$14M | -88.0% | -1382.5% | -13.9% | -8.2% | -$11M | — | $43M |
How the market has priced IMDX against its own fundamentals since 2025-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Insight Molecular Diagnostics Inc.'s revenue has grown 27.2% per year. These are computed facts, not advice.
As of FY2025, Insight Molecular Diagnostics Inc. reported — of total debt against $12M of cash.
In FY2025, gross margin was 56.7%, operating margin -1260.8%, and net margin -1.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.